Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (AZN) will increase investment in a new Virginia manufacturing facility to $4.5 billion, a $500m boost to expand capability to produce a broader range of medicines including weight‑management small molecules and antibody drug conjugate (ADC) cancer therapies.
The Rivanna Futures site in Albemarle County is expected to create approximately 3,600 jobs (about 600 ongoing skilled roles and 3,000 construction roles). Work starts immediately and the facility is expected to be operational in 4–5 years. The project is part of a $50 billion U.S. R&D and manufacturing commitment and will deploy AI, automation, and data analytics.
Turbine announced a collaboration with AstraZeneca (AZN) on October 9, 2025 to apply Turbine's virtual disease models to antibody-drug conjugate (ADC) discovery.
The partnership will use a lab-in-the-loop workflow where Turbine recommends a strategic subset of cell lines for wet-lab testing, then predicts outcomes across thousands of in silico models using AstraZeneca's ADC datasets, covering single-agent and combination studies. Goals include reducing large-scale cell line screening, improving speed and efficiency of ADC discovery, and delivering mechanistic insights by modeling cell survival and gene-expression changes to inform ADC positioning and clinical translatability.
AstraZeneca (NYSE:AZN) announced that baxdrostat met the primary endpoint in the Phase III Bax24 trial, showing a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure versus placebo at Week 12 in patients with resistant hypertension.
The randomized, double-blind study randomized 218 participants 1:1 to baxdrostat 2 mg or placebo for a 12-week double-blind period. Efficacy was observed across the full 24-hour period, including the high-risk early morning window. Baxdrostat was generally well tolerated with a safety profile consistent with prior BaxHTN results. Data will be shared with regulators and presented at AHA Scientific Sessions November 2025.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced positive Phase III TROPION-Breast02 results for DATROWAY (datopotamab deruxtecan-dlnk) on October 6, 2025.
DATROWAY showed a statistically significant, clinically meaningful improvement in overall survival (OS) and a highly statistically significant improvement in progression-free survival (PFS) versus investigator's choice chemotherapy as 1st-line treatment for metastatic triple-negative breast cancer (TNBC) patients for whom immunotherapy was not an option. Approximately 70% of metastatic TNBC patients are not candidates for immunotherapy.
The safety profile was consistent with prior trials; common adverse reactions included stomatitis (63%), ocular reactions (36%), and ILD/pneumonitis observed in the pooled breast-cancer population at 3.6% (one fatal case, 0.2%). Data will be presented at a medical meeting and shared with regulators.
AstraZeneca (AZN) and Daiichi Sankyo reported positive topline results from the phase 3 TROPION-Breast02 trial: DATROWAY (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus investigator’s choice chemotherapy as first-line therapy for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option. The PR also states a highly statistically significant improvement in progression-free survival (PFS) (dual primary endpoints). The companies say plans for global regulatory submissions are underway and that the DATROWAY safety profile was consistent with prior trials. Data will be presented at an upcoming medical meeting and companies are running three additional phase 3 TNBC trials.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo announced that the FDA has accepted their supplemental Biologics License Application (sBLA) for ENHERTU® followed by THP for review in high-risk HER2-positive early-stage breast cancer patients prior to surgery.
The application is based on the DESTINY-Breast11 phase 3 trial, which demonstrated statistically significant improvements in pathologic complete response (pCR) rates compared to standard treatment. The trial also showed an improved safety profile and early positive trend in event-free survival. The FDA target action date is set for May 18, 2026.
This potential approval could represent a new treatment approach for patients with high-risk HER2-positive early-stage breast cancer, where currently nearly half of patients don't achieve pCR with existing neoadjuvant treatments.
AstraZeneca (NYSE:AZN) announced positive results from the DESTINY-Breast05 Phase III trial, showing that ENHERTU demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to T-DM1 in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment.
This marks the second positive Phase III trial for ENHERTU in HER2-positive early breast cancer, following earlier success in the DESTINY-Breast11 trial. The safety profile remained consistent with known data, with no new concerns identified. Overall survival data was not mature at this interim analysis.
The results will be presented at ESMO 2025 in a Presidential Symposium, and data will be shared with global regulatory authorities. The trial was conducted in collaboration with major research groups including NSABP Foundation, German Breast Group, AGO-B, and SOLTI.
AstraZeneca (NYSE:AZN) announced positive topline results from the DESTINY-Breast05 phase 3 trial of ENHERTU® in HER2-positive early breast cancer patients. The trial demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival compared to T-DM1 in patients with residual disease after neoadjuvant treatment.
This marks the second positive phase 3 trial for ENHERTU in HER2-positive early breast cancer, following successful DESTINY-Breast11 results earlier this year. The safety profile remained consistent with previous findings, with no new concerns identified. Both trials' results will be presented at ESMO 2025's Presidential Symposium, and regulatory submissions are currently being prepared.
AstraZeneca (NYSE:AZN) has announced the launch of AstraZeneca Direct, a new direct-to-consumer online platform that will provide eligible US patients with access to prescribed medications at reduced prices with home delivery. Starting October 1, 2025, patients can purchase medicines like AIRSUPRA and FARXIGA at up to 70% off list price, along with FLUMIST for home delivery.
The platform aims to support patients with chronic conditions such as asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection. This initiative complements AstraZeneca's existing patient support services, which will continue unchanged for eligible patients, offering medications at no or reduced cost.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced that their ENHERTU plus pertuzumab combination therapy has received Priority Review from the FDA for first-line treatment of HER2-positive metastatic breast cancer. The decision is based on the groundbreaking DESTINY-Breast09 Phase III trial results, which demonstrated a 44% reduction in disease progression or death risk compared to standard treatment.
The trial achieved a remarkable median progression-free survival of 40.7 months with ENHERTU plus pertuzumab versus 26.9 months for the current standard treatment. The combination therapy showed an impressive 85.1% objective response rate with 58 complete responses. The FDA's decision is expected in Q1 2026, potentially establishing a new standard of care in the first-line setting where approximately 10,000 patients are treated annually in the US.